During the last session, Akebia Therapeutics Inc (NASDAQ:AKBA)’s traded shares were 10.58 million, with the beta value of the company hitting 0.77. At the end of the trading day, the stock’s price was $2.62, reflecting an intraday gain of 6.50% or $0.16. The 52-week high for the AKBA share is $2.89, that puts it down -10.31 from that peak though still a striking 69.47% gain since the share price plummeted to a 52-week low of $0.80. The company’s market capitalization is $685.88M, and the average trade volume was 4.14 million shares over the past three months.
Akebia Therapeutics Inc (AKBA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AKBA has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.
Akebia Therapeutics Inc (NASDAQ:AKBA) trade information
Akebia Therapeutics Inc (AKBA) registered a 6.50% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.50% in intraday trading to $2.62, hitting a weekly high. The stock’s 5-day price performance is 9.62%, and it has moved by 55.95% in 30 days. Based on these gigs, the overall price performance for the year is 75.84%.
The consensus price target of analysts on Wall Street is $6.5, which implies an increase of 59.69% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $7 respectively. As a result, AKBA is trading at a discount of -167.18% off the target high and -129.01% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 32.58%. While earnings are projected to return 67.88% in 2025.
AKBA Dividends
Akebia Therapeutics Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 9.28 million shares, is of VANGUARD GROUP INC’s that is approximately 4.4235% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $9.46 million.
Also, the Mutual Funds coming in first place with the largest holdings of Akebia Therapeutics Inc (AKBA) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 5.95 shares. This amounts to just over 2.27 percent of the company’s overall shares, with a $15.58 million market value. The same data shows that the other fund manager holds slightly less at 5.79, or about 2.21% of the stock, which is worth about $15.18 million.
